Business
Nutriband Inc. to Officially Launch AI Tape brand in Q1 2023
ORLANDO, FL / ACCESSWIRE / December 29, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) announced today that it has begun production of its AI Tape brand
About this update from Nutriband Inc.
[{"type":"text","content":"ORLANDO, FL / ACCESSWIRE / December 29, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) announced today that it has begun production of its AI Tape brand with an expected launch of the product line in Q1 2023.AI Tape is designed to share many of the benefits of traditional Kinesiology Tape. AI Tape further adds soothing and therapeutic ingredients held in suspension with a proprietary adhesive mix.AI Tape is manufactured in the USA at the Company's Pocono Pharmaceutical facility in North Carolina.About Nutriband Inc.We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse deterrent fentanyl patch incorporating our AVERSA™ abuse deterrence technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.The Company's website is www.nutriband.com. Any material contained in or derived from the Company's websites or any other website is not part of this press release.Forward-Looking StatementsCertain statements contained in this press release, including, without limitation, statements containing the words ‘'believes,\" \"anticipates,\" \"expects\" and words of similar import, constitute \"forward-looking statements\" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company's actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company's ability to develop its proposed abuse deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personn...